International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 4, April 2025 **ijppr.humanjournals.com** ISSN: 2349-7203

An Overview of Nano Structured Lipid Carriers

Swaraj S. Warkad[1*], Shyam S. Awate[2], Yuraj P. Kadam[3], Sanjay R. Arote [4],Ramprasad D. Kadam[1], Mangesh M. Galbale[1],Mahadevan R. Swamy[5].

[1]M. Pharm student, Department of Pharmaceutics, Krishnarao Bhegade Indrayani Institute of Pharmaceutical Education and Research, Talegaon Dabhade, Maval, Pune - 410507. India.

[2]Associate Professor, Department of Pharmaceutics, Krishnarao Bhegade Indrayani Institute of Pharmaceutical Education and Research, Talegaon Dabhade, Maval, Pune - 410507. India.

[3]M. Pharm student, Department of Pharmaceutics, Sudharkarao Naik Institute of Pharmacy, Pusad, Yavatmal –440504. India.

[4]Principal, Krishnarao Bhegade Indrayani Institute of Pharmaceutical Education and Research, Talegaon Dabhade, Maval, Pune – 410507 India.

[5]Assistant Professor,Department of Medicinal Chemistry, Krishnarao Bhegade Indrayani Institute of Pharmaceutical Education and Research, Talegaon Dabhade, Maval, Pune - 410507. India.

Received: 2025-4-01 Revised: 2025-4-12 Accepted: 2025-4-20

ABSTRACT :

Nanostructured Lipid Carriers (NLCs) are emerging as a versatile and advanced drug delivery system, combining the benefits of solid lipid nanoparticles and traditional lipid emulsions. NLCs consist of a solid lipid core and a liquid lipid shell, allowing for enhanced drug solubility, improved bioavailability, and controlled drug release. This unique structure addresses the challenge of poor water solubility in many pharmacologically active compounds, making NLCs highly effective for delivering both hydrophilic and lipophilic drugs. The solid-liquid lipid matrix provides a stable encapsulation environment, preventing drug expulsion and ensuring sustained release. NLCs are compatible with a variety of therapeutic agents, including anticancer, anti-inflammatory, and antioxidant drugs. Their biocompatibility, biodegradability, and ability to be modified for targeted delivery make them suitable for various administration routes, such as oral, intravenous, transdermal, and ocular delivery. Several manufacturing techniques, such as high-pressure homogenization and microfluidics, have been developed to produce NLCs with optimized particle size, stability, and drug loading capacity. Despite their promising potential, challenges such as scalability, regulatory hurdles, and stability during storage need to be addressed. Future research focusing on improving production techniques, enhancing formulation stability, and integrating NLCs with personalized medicine approaches holds promise for advancing NLCs in clinical applications.

Keywords: Nanostructured Lipid Carriers (NLCs), Drug Delivery, Bioavailability, Controlled Drug Release, Solid Lipid Nanoparticles (SLNs), Micro fluidics, Targeted Delivery, Hydrophilic and Lipophilic Drugs, Biocompatibility

Abbreviations: Nanostructured Lipid Carriers (NLCs), Solid Lipid Nanoparticles (SLNs), Polyvinyl alcohol (PVA), High Pressure Homogenization (HPH),Carbon Dioxide (CO_2), intravenous (IV), reticuloendothelial system (RES).

Introduction on Nanostructured Lipid Carriers (NLCs):

Nanostructured lipid carriers (NLCs) represent an innovative approach in the field of drug delivery systems, combining the advantages of solid lipid nanoparticles (SLNs) and conventional lipid emulsions. NLCs are a type of drug delivery system that has a solid lipid core encased in a liquid lipid shell. It was created to increase lipophilic medications' solubility and bioavailability. This unique architecture allows for the encapsulation of a wide range of therapeutic agents while improving stability, controlled release, and targeting capabilities. [1][2]

One of the significant challenges in drug delivery is the poor water solubility of many pharmacologically active compounds. NLCs address this issue by utilizing lipids that can enhance the solubilization of these compounds, facilitating their absorption and therapeutic efficacy[3]. Furthermore, the nanoscale size of these carriers improves their circulation time in the bloodstream, allowing for better distribution to target tissues. [4]

The design of NLCs is versatile, enabling the incorporation of various types of drugs, including anticancer agents, anti-inflammatory drugs, and antioxidants. Their ability to encapsulate both hydrophilic and lipophilic drugs makes them suitable for a broad spectrum of applications, from cancer therapy to chronic disease management[5]. Additionally, the biocompatibility and biodegradability of the lipid materials used in NLCs further contribute to their appeal, reducing the risk of toxicity associated with synthetic polymer carriers. Moreover, NLCs can be engineered to achieve controlled and sustained release profiles, minimizing side effects and enhancing therapeutic outcomes[1][2]. By modifying their surface properties, such as through the addition of targeting ligands or stealth technologies, NLCs can also improve cellular uptake and specificity, making them promising candidates for targeted drug delivery systems[3].In summary, nanostructured lipid carriers offer a multifaceted solution to the challenges of drug delivery, with their potential to improve bioavailability, enhance therapeutic efficacy, and facilitate target treatment. Continued research and development in this area hold the promise of significant advancements in the field of pharmaceutical formulations and patient care [4][5].

Structure of Nanostructured Lipid Carriers (NLCs):

The unique structure of NLCs consists of both solid and liquid lipids, which form a matrix with higher drug loading capacity compared to solid lipid nanoparticles (SLNs) [6]. An "imperfect crystal" structure is produced when liquid lipids are present because they cause disruption to the solid lipid matrix. [7]. This prevents the expulsion of drugs during storage and provides a stable environment for drug encapsulation. There are three main types of NLCs based on their structure:

1. **Imperfect Crystal Type**: Features an irregular crystal lattice that allows for greater drug encapsulation [8].



Fig.1 Imperfect Crystal Type

2. **Multiple Type**: Oil droplets are dispersed in the solid lipid matrix, providing a reservoir for drug release [9].



Fig.2Multiple Type

3. **Amor phous Type**: Solid lipids exist in a non-crystalline form, reducing the risk of drug expulsion during storage [10].



Fig.3Amorphous Type

NLCs' structure not only enhances drug loading but also facilitates sustained release of active pharmaceutical ingredients. This is beneficial for conditions requiring long-term treatment or localized drug delivery [11]. NLCs are typically composed of three main components: solid lipids, liquid lipids, and surfactants. One way to characterize the entire structure is The general arrangement can be explained as follows:

1. **Solid Lipid Core**:

o The core of NLCs is formed by solid lipids, which are solid at room temperature. These lipids provide structural stability and protect the encapsulated drug from degradation [12].

o Common solid lipids used include glyceryl monostearate, cetyl palmitate, and stearic acid [8].

o The choice of solid lipid affects the release profile and stability of the NLC [7].

2. **Liquid Lipid Shell**:

o Surrounding the solid lipid core is a liquid lipid phase, which remains liquid at room temperature. This component enhances drug solubility and allows for higher drug loading [9].

o Typical liquid lipids include medium-chain triglycerides, oleic acid, and other oils [12].

o The liquid lipid phase also contributes to the flexibility of the NLC structure, enabling better adaptation to biological environments [10].

3. **Surfactants/Emulsifiers**:

o To stabilize the NLCs and prevent aggregation, surfactants or emulsifiers are added. These compounds lower the interfacial tension between the lipids and the aqueous environment [11].

o Common surfactants include polysorbates (e.g., Tween 80), phospholipids, and polyvinyl alcohol (PVA) [12].

o Surfactants also play a crucial role in controlling the size and surface properties of the NLCs [8].

Composition of Nanostructured Lipid Carriers (NLCs):

The composition of NLCs is crucial for their performance, influencing aspects such as drug loading capacity, release kinetics, and stability. Here are some key factors:

1. Drug Selection:

o Numerous medicinal substances, including hydrophilic and lipophilic medications, can be encapsulated in NLCs.

- . The choice of drug affects the selection of lipids and the formulation process [10].

- Ratio of Solid to Liquid Lipid:

- The ratio of solid to liquid lipids is a critical parameter. A higher solid lipid content can enhance stability but may limit drug loading. Conversely, a higher liquid lipid phase can increase drug solubility but may affect structural integrity [11].

2. Surfactant Type and Concentration:

- The type and concentration of surfactants impact the stability and size of the NLCs. Surfactants can also influence drug release profiles, making their selection essential for specific applications [12].

3. Particle Size and Distribution:

- NLCs typically range in size from 50 nm to 500 nm. Smaller particles may improve cellular uptake, while larger particles can enhance stability and retention in circulation [9].

4. Zeta Potential:

The zeta potential indicates the surface charge of the NLCs, which affects their stability and interactions with biological membranes Stability can be increased by preventing aggregation with a higher zeta potential[11].

5. Manufacturing Techniques:

Several methods have been developed for the preparation of NLCs. The most commonly used techniques include:

1) **High-Pressure Homogenization (HPH)**

Description:

This technique involves the application of high pressure to disperse lipid materials into nanosized particles.
Process:

• Solid lipids are melted and mixed with liquid lipids and the drug.

• The mixture is emulsified in an aqueous phase containing surfactants.

• The emulsion is then subjected to high pressure (typically 500-2000 bar) in a homogenizer.

• The high shear forces break down the lipid droplets into nanoparticles.

Advantages:

• Produces narrow particle size distribution.

• Scalable for industrial production.

Limitations:

• Requires expensive equipment.

• Temperature-sensitive drugs may degrade.[13, 14].

2) **Ultrasonication**

Description:

Ultrasonication uses high-frequency sound waves to generate cavitation bubbles in a liquid medium, leading to the disruption of lipid structures.

Process:

• Similar to HPH, solid and liquid lipids are melted and mixed with the drug.

• In an aqueous phase, the mixture is emulsified.

• Ultrasonic waves are applied to the emulsion to produce nanosized particles.

Advantages:

• Simple and cost-effective.

• Suitable for small-scale production.

Limitations:

• Limited scalability for larger batches.

• May lead to heat generation, risking drug stability.[14, 15].

3) **Solvent Evaporation**

Description:

In this technique, the lipid components are dissolved in a volatile organic solvent, which is then evaporated to form nanoparticles.

Process:

• Lipids and the drug are dissolved in a suitable organic solvent.

• Drop by drop, the solution is stirred into an aqueous phase containing surfactants.

• The solvent evaporates, resulting in the formation of NLCs.

Advantages:

•Easy and efficient way to encapsulate medications that are hydrophobic.

• The finished good can still include residual solvent.

Limitations:

• The finished product may contain residual solvent..

• Scale-up can be challenging.[16, 17]

4) **Melt Emulsification**

Description:

This method combines solid and liquid lipids in a melted state before emulsification.

Process:

• The solid lipid is melted and mixed with the liquid lipid and drug.

• The mixture is emulsified with an aqueous phase using mechanical stirring.

• The emulsion is cooled, causing solidification and formation of NLCs.

Advantages:

• Mild processing conditions, preserving thermolabile compounds.

• Simple and reproducible.

Limitations:

• Potential for coalescence of particles if not controlled.[15, 16]

5) **Microfluidics**

Description:

Microfluidic techniques use microchannels to precisely control fluid flows, leading to the formation of nanosized droplets.

Process:

• Lipids and drug are injected into microchannels.

• The controlled mixing with the aqueous phase generates small droplets.

• The droplets solidify into NLCs as they flow through the channels.

Advantages:
• exact control of particle size and dispersion.

• High-throughput production.

Limitations:

• Equipment can be expensive.

• Limited scalability for very large batches.[17,18]

6) **Precipitation Method**

Description:

This method involves the precipitation of lipids and drug from a solution to form nanoparticles.

Process:

• Organic solvation breaks down lipids.

• The solution is rapidly mixed with a non-solvent (usually water), causing lipid and drug precipitation.

• NLCs are collected through centrifugation or filtration.

Advantages:

• Suitable for drugs with poor solubility.

• No high energy input required.

Limitations:

• Requires careful optimization to avoid agglomeration.

• Limited control over particle size.[16, 18]

7) **Supercritical Fluid Technology**

Description:

This technique utilizes supercritical fluids (like CO2) as solvents to create nanoparticles.

Process:

• Supercritical CO2 dissolves both lipids and medicines.

• The mixture is rapidly depressurized, leading to the formation of NLCs.

Advantages:

• Environmentally friendly due to the use of supercritical CO_2.

• There are no leftover solvents in the finished work.

Limitations:

• Requires specialized equipment.

• High operational costs.[19]

Routes of Administration:

NLCs are versatile and can be delivered through various routes, each offering unique benefits:

1) **Oral Administration**

Description:

NLCs can be formulated for oral delivery, providing a non-invasive route for drug administration.

Advantages:

• Improved bioavailability of lipophilic drugs.

• Improved absorption resulting from the nano-sized composition.

• Potential for sustained release and reduced dosing frequency.

Challenges:

• Stability of NLCs in the gastrointestinal tract (pH changes, enzymes).

• Potential degradation of sensitive drugs.

• Variability in absorption due to individual physiological differences.[20, 21, 22]

2) **Intravenous Administration**

Description:

NLCs can be administered via intravenous (IV) injection, allowing direct entry into the bloodstream.

Advantages:

• Rapid onset of action.

• Strong bioavailability since the medicine avoids first-pass metabolism.

• Ability to deliver high doses of drugs directly to the target site.

Challenges:

• Risk of toxicity and adverse reactions, especially with certain surfactants.

• Need for strict sterility and stability of the formulation.

• Prospect for reticuloendothelial system (RES) clearance and aggregation.[21, 23]

3) **Topical Administration**

Description:

NLCs can be applied directly to the skin for localized treatment or systemic absorption.

Advantages:

• Enhanced penetration through the skin due to nanoscale size.

• Reduced systemic side effects when targeting local conditions (e.g., psoriasis, eczema).

• Ability to encapsulate both hydrophilic and lipophilic drugs Capacity to encapsulate medicines that are lipophilic and hydrophilic..

Challenges:

• Limited permeability for larger therapeutic agents.

• Potential irritation or allergic reactions to excipients.

• skin type and condition-related variations in skin absorption.[22, 24]

4) **Transdermal Administration**

Description:

NLCs can be formulated for transdermal delivery, allowing drugs to penetrate the skin barrier for systemic effects.

Advantages:

• Non-invasive and convenient for patients.

• Sustained release of drugs over extended periods.

• Reduced first-pass metabolism.

Challenges:

• Formulation must ensure adequate skin penetration.

• Potential for irritation or sensitization.

• Requires optimization of particle size and composition for effective delivery.[24, 25]

5) **Inhalation Administration**

Description:

NLCs can be delivered via inhalation for treating respiratory diseases.

Advantages:

• Rapid absorption through the pulmonary route.

• Direct delivery to the lungs, improving local therapeutic effects.

• Reduced systemic side effects.

Challenges:

• Requires optimization of particle size for efficient aerosolization and deposition in the lungs.

• Stability of NLCs in the aerosol form.

• Potential for irritation of the respiratory tract.[25, 26]

6) **Ocular Administration**

Description:

NLCs can be formulated for eye drops or gels for treating ocular diseases.

Advantages:

• Improved drug bioavailability in the eye due to enhanced permeability.

• extended duration of retention on the surface of the eyes.

• Reduced systemic absorption and side effects.

Challenges:

• Formulation stability and compatibility with ocular tissues.

• Potential for irritation or discomfort.

• Limited penetration to deeper ocular tissues.[23, 26]

7) **Nasal Administration**

Description:

NLCs can be administered through the nasal route for local or systemic effects.

Advantages:

• Due to the nasal mucosa's strong vascularization, there is rapid absorption.

• Bypasses first-pass metabolism.

• Useful for vaccines and peptides that require rapid delivery.

Challenges:

• restricted nasal cavity volume capacity.

• Potential for irritation or discomfort.

• Variability in absorption among individuals.[24, 25]

8) **Intratumoral Administration**

Description:

Direct injection of NLCs into tumors for localized treatment.

Advantages:

• High local drug concentration, reducing systemic exposure.

• Possibility of improved medication accumulation inside the tumor.

• Bypasses biological barriers, improving therapeutic efficacy.

Challenges:

• Invasive procedure with potential complications.

• Limited to accessible tumors.

• Requires precise delivery techniques.[22, 26]

Applications in Drug Delivery:

NLCs have found applications across several therapeutic areas, including:

1) **Oral Drug Delivery**

Overview:

NLCs enhance the bioavailability of poorly soluble drugs when administered orally.

Applications:

a. Improved Solubility: NLCs can encapsulate lipophilic drugs, improving their solubility and absorption in the gastrointestinal tract 27.

b. Controlled Release: They provide sustained release profiles, reducing the need for frequent dosing 27.

c. Targeted Delivery: NLCs can be modified with ligands to target specific receptors in the gut, enhancing the therapeutic effect 28.
Examples:

d. Delivery of anti-cancer drugs (e.g., paclitaxel).

e. Anti-inflammatory agents for conditions like arthritis 29.

2) **Topical and Transdermal Delivery**

Overview:

NLCs are used to enhance drug penetration through the skin, making them suitable for localized treatments or systemic absorption 30.

Applications:

a. Skin Disorders: They are effective in delivering anti-inflammatory agents, corticosteroids, and anti-fungal drugs to treat skin conditions like psoriasis and eczema 31.

b. Pain Management: NLCs can deliver analgesics or anesthetics transdermally for localized pain relief 30.
Examples:

c. Formulations for treating acne or eczema.

d. Pain relief gels containing lidocaine 30.

3) **Intravenous Delivery**

Overview:

NLCs provide an effective means for intravenous administration of drugs, especially those that are poorly soluble 27.
Applications:

a. Targeted Cancer Therapy: NLCs can encapsulate chemotherapeutic agents, allowing for targeted delivery to tumor sites and reducing systemic toxicity 32.

b. Antibiotic Delivery: NLCs can enhance the solubility and stability of antibiotics, improving their efficacy 29.
Examples:

c. Delivery of doxorubicin for cancer treatment.

d. Administration of antibiotics like vancomycin 28.

4) **Inhalation Delivery**

Overview:

NLCs can be aerosolized for inhalation, providing a direct route to the lungs for respiratory therapies 33.
Applications:

a. Pulmonary Drug Delivery: NLCs can effectively deliver drugs for conditions like asthma or chronic obstructive pulmonary disease (COPD) 34.

b. Vaccine Delivery: They can be used in the formulation of inhalable vaccines for rapid immune response 30.
Examples:

c. Delivery of bronchodilators like salbutamol.

d. Aerosolized vaccines for respiratory pathogens 33.

5) **Ocular Drug Delivery**

Overview:

NLCs are suitable for formulating eye drops and gels for treating ocular diseases 28.

Applications:

a. Enhanced Bioavailability: They improve the retention time of drugs on the ocular surface, leading to better therapeutic outcomes 31.

b. Sustained Release: NLCs can provide prolonged release of drugs for chronic eye conditions 27.

Examples:

c. Delivery of anti-glaucoma medications.

d. Treatments for dry eye syndrome 32.

6) **Nasal Drug Delivery**

Overview:

It is possible to prepare NLCs for nasal delivery, which offers quick absorption and activity. 29.

Applications:

a. Systemic Delivery of Peptides and Proteins: NLCs can deliver biologics that would otherwise be degraded by the gastrointestinal tract 30.

b. Local Treatment: They can be used for treating nasal allergies and infections 33.

Examples:

c. Delivery of insulin for diabetes management.

d. Formulations for treating allergic rhinitis 30.

7) **Intratumoral Delivery**

Overview:

NLCs can be injected directly into tumors for localized treatment 34.

Applications:

a. Targeted Cancer Therapy: They allow for high local concentrations of chemotherapy while minimizing systemic exposure 32.

b. Combination Therapy: NLCs can carry multiple therapeutic agents for synergistic effects 28.

Examples:

c. Delivery of chemotherapeutics like cisplatin directly to tumor sites 34.

d. Co-delivery of chemotherapeutics and immunotherapeutics 33.

Challenges and Future Perspectives:

A. Challenges:

1. Scalability of Production

o Description: Many production methods for NLCs, such as high-pressure homogenization and microfluidics, can be expensive and difficult to scale for large-scale manufacturing.

o Impact: Limited scalability can hinder the commercial viability of NLC formulations. [36]

2. Stability Issues

o Description: NLCs can face stability issues during storage, leading to particle aggregation or drug leakage over time.

o Impact: Instability can compromise the efficacy and safety of drug formulations. [35]

3. Regulatory Hurdles

o Description: The regulatory framework for nanocarrier-based formulations is still evolving, leading to uncertainty in approval processes.

o Impact: Lengthy and complex regulatory pathways may delay market entry. [37]

4. Characterization Challenges

o Description: Standardized methods for characterizing the physical and chemical properties of NLCs are still being developed.

o Impact: Inconsistent characterization can affect reproducibility and quality assurance. [38]

5. Bioavailability and Pharmacokinetics

o Description: While NLCs improve the solubility of lipophilic drugs, predicting their pharmacokinetics and bioavailability can be complex due to varying biological environments.

o Impact: Variability in bioavailability can affect therapeutic outcomes. [39]

6. Targeting and Distribution

o Description: Achieving specific targeting of NLCs to desired tissues or cells can be challenging, especially in complex biological systems.

o Impact: Lack of targeted delivery can result in reduced efficacy and increased side effects.

7. Patient Acceptance

o Description: Acceptance of new drug delivery systems can vary among patients, especially for routes of administration that are less conventional.

o Impact: Low acceptance may limit the use of NLC formulations in certain patient populations.

B. Future Perspectives:

1. Advancements in Manufacturing Techniques

- Outlook: Development of more cost-effective, scalable manufacturing methods, such as 3D printing and microfluidics, could enhance large-scale production of NLCs.

2. Enhanced Formulation Stability

- Outlook: Research into stabilizers and encapsulation techniques (e.g., using polymers or surfactants) can help improve the stability of NLC formulations. [35]

3. Improved Regulatory Framework

- Outlook: As the field matures, clearer regulatory guidelines specifically for nanocarriers can facilitate faster approval processes. [37]

4. Standardization of Characterization Methods

- Outlook: Establishing standardized protocols for the characterization of NLCs will enhance reproducibility and quality control in manufacturing. [38]

5. Personalized Medicine Approaches

- Outlook: NLCs can be tailored to individual patient profiles, improving targeting and efficacy through personalized drug delivery systems.

6. Integration with Other Technologies

- Outlook: Combining NLCs with other technologies, such as stimuli-responsive materials or smart delivery systems, could enhance targeting and controlled release capabilities.

7. Public and Patient Education

- Outlook: Increasing awareness and education about the benefits and safety of NLCs can improve patient acceptance and adherence to treatments.

8. Expanded Applications

- Outlook: Ongoing research can lead to the development of NLCs for novel applications, such as gene delivery, vaccines, and combination therapies.

Conclusion:

Drug delivery systems have found a highly promising and adaptable platform in nanostructured lipid carriers, or NLCs. Their unique structure, comprising a solid lipid core and liquid lipid phase, enables enhanced drug solubility, bioavailability, and sustained release of both hydrophilic and lipophilic drugs. NLCs address significant challenges in conventional drug delivery, particularly in improving the solubility and stability of poorly water-soluble drugs, while minimizing side effects and enhancing therapeutic outcomes.

The versatility of NLCs allows for their use across multiple administration routes, including oral, intravenous, transdermal, ocular, and inhalation, making them suitable for a wide range of therapeutic applications. Moreover, the ability to tailor NLC formulations for specific drug delivery needs, combined with their biocompatibility and potential for targeted delivery, underscores their potential in areas such as cancer therapy, chronic disease management, and localized treatments.

However, despite the advancements in NLC design and production techniques, challenges remain. Issues such as scalability, regulatory approval, and stability during long-term storage need to be addressed to fully realize the clinical and commercial potential of NLCs. Continued research and technological advancements, particularly in production methods and formulation stability, will be key to overcoming these hurdles and unlocking the full potential of NLCs as a next-generation drug delivery system.

REFERENCES:-

1. Müller, R. H., Peters, J., & Kralj, M.. "Nanostructured lipid carriers (NLC) in drug delivery." Advanced Drug Delivery Reviews (2001), 47(2-3), 189-203.DOI: 10.1016/S0169-409X(01)00163-2
2. Wissing, S. A., & Müller, R. H.. "The influence of the lipid matrix on the drug release from solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)." International Journal of Pharmaceutics,(2003), 253(1-2), 121-127. DOI: 10.1016/S0378-5173(02)00413-2
3. Kumar, A., & Yadav, S. K.. "Nanostructured lipid carriers (NLC): A novel drug delivery system." International Journal of Pharmaceutical Sciences and Research, (2016), 7(5), 1973-1981. DOI: 10.13040/IJPSR.0975-8232.7(5).1973-81
4. Patel, P. J., & Patel, M. M.. "Nanostructured lipid carriers: A novel approach for drug delivery." Journal of Drug Delivery Science and Technology, (2013), 23(5), 574-581. DOI: 10.1016/S1773-2247(13)50039-7
5. Duarte, J. L., & Valenzuela, C.. "Nanostructured lipid carriers: Design, characterization and applications." Biomaterials Science, (2017) 5(6), 917-927. DOI: 10.1039/C7BM00142A
6. Müller, R. H., & Lucks, J.. "Nanostructured lipid carriers (NLC) in drug delivery." Journal of Drug Delivery Science and Technology, (2015) 30, 98-105.DOI: 10.1016/j.jddst.2015.07.004
7. Wissing, S. A., & Müller, R. H.. "The influence of the lipid matrix on the drug release from solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)." International Journal of Pharmaceutics, (2003), 253(1-2), 121-127.DOI: 10.1016/S0378-5173(02)00413-2
8. Kumar, A., & Yadav, S. K.. "Nanostructured lipid carriers (NLC): A novel drug delivery system." International Journal of Pharmaceutical Sciences and Research, (2016), 7(5), 1973-1981.DOI: 10.13040/IJPSR.0975-8232.7(5).1973-81
9. Patel, P. J., & Patel, M. M.. "Nanostructured lipid carriers: A novel approach for drug delivery." Journal of Drug Delivery Science and Technology, (2013), 23(5), 574-581.DOI: 10.1016/S1773-2247(13)50039-7.
10. Duarte, J. L., & Valenzuela, C.. "Nanostructured lipid carriers: Design, characterization and applications." Biomaterials Science, (2017), 5(6), 917-927.DOI: 10.1039/C7BM00142A
11. Pignatello, R., & Puglisi, G.. "Nanostructured lipid carriers for drug delivery." Current Drug Delivery, (2010) 7(3), 313-320. DOI: 10.2174/156720110791278371
12. Patel, K. J., & Patel, M. M.. "Nanostructured lipid carriers: An overview." International Journal of Pharma and Bio Sciences, (2012), 3(4), 707-719.
DOI: 10.22376/ijpbs.2012.3.4.a707-719
13. Müller, R. H., & Lucks, J.. "Nanostructured lipid carriers (NLC) in drug delivery." Journal of Drug Delivery Science and Technology, (2015).30, 98-105.DOI: 10.1016/j.jddst.2015.07.004
14. Wissing, S. A., & Müller, R. H.. "Solid lipid nanoparticles and nanostructured lipid carriers: Production, characterization, and applications." Advanced Drug Delivery Reviews, 54(Supplement), (2002). S13-S21.DOI: 10.1016/S0169-409X(02)00173-4
15. Kumar, A., & Yadav, S. K.. "Nanostructured lipid carriers (NLC): A novel drug delivery system." International Journal of Pharmaceutical Sciences and Research, (2016). 7(5), 1973-1981.DOI: 10.13040/IJPSR.0975-8232.7(5).1973-81
16. Patel, K. J., & Patel, M. M.. "Nanostructured lipid carriers: A novel approach for drug delivery." Journal of Drug Delivery Science and Technology, (2013).23(5), 574-581.DOI: 10.1016/S1773-2247(13)50039-7
17. Duarte, J. L., & Valenzuela, C.. "Nanostructured lipid carriers: Design, characterization and applications." Biomaterials Science, (2017). 5(6), 917-927.DOI: 10.1039/C7BM00142A
18. Müller, R. H., & Wissing, S. A.. "Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) – a novel approach for drug delivery."European Journal of Pharmaceutics and Biopharmaceutics, (2002). 54(1), 161-168.
DOI: 10.1016/S0939-6411(02)00138-0
19. Daniyal, M., & Khan, M.. "Nanostructured lipid carriers: An overview." International Journal of Drug Delivery Technology, (2018). 8(1), 32-39.DOI: 10.25258/ijddt.v8i1.18112
20. Müller, R. H., & Lucks, J.. "Nanostructured lipid carriers (NLC) in drug delivery." Journal of Drug Delivery Science and Technology, (2015). 30, 98-105.DOI: 10.1016/j.jddst.2015.07.004
21. Patel, P. J., & Patel, M. M.. "Nanostructured lipid carriers: A novel approach for drug delivery." Journal of Drug Delivery Science and Technology, (2013).23(5), 574-581.DOI: 10.1016/S1773-2247(13)50039-7
22. Kumar, A., & Yadav, S. K.. "Nanostructured lipid carriers (NLC): A novel drug delivery system." International Journal of Pharmaceutical Sciences and Research(2016), 7(5), 1973-1981.DOI: 10.13040/IJPSR.0975-8232.7(5).1973-81
23. Wissing, S. A., & Müller, R. H.. "The influence of the lipid matrix on the drug release from solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)." International Journal of Pharmaceutics, (2003). 253(1-2), 121-127.
DOI: 10.1016/S0378-5173(02)00413-2
24. Duarte, J. L., & Valenzuela, C.. "Nanostructured lipid carriers: Design, characterization and applications." Biomaterials Science, (2017). 5(6), 917-927.DOI: 10.1039/C7BM00142A
25. Sinha, V. R., & Kumria, R.. "Nanoemulsion for the oral delivery of poorly soluble drugs: A review." Nanomedicine: Nanotechnology, Biology and Medicine, (2003). 4(2), 139-147.DOI: 10.1016/j.nano.2008.06.002

26. Yuan, H., & Chen, X.. "Nanostructured lipid carriers: An overview." Journal of Nanomedicine & Nanotechnology, (2015).6(3), 1-8.DOI: 10.4172/2157-7439.1000322
27. Müller, R. H., & Lucks, J.. "Nanostructured lipid carriers (NLC) in drug delivery." Journal of Drug Delivery Science and Technology, (2015).30, 98-105.DOI: 10.1016/j.jddst.2015.07.00
28. Wissing, S. A., & Müller, R. H.. "Solid lipid nanoparticles and nanostructured lipid carriers: Production, characterization, and applications." Advanced Drug Delivery Reviews, 54(Supplement), (2002). S13-S21.DOI: 10.1016/S0169-409X(02)00173-4
29. Patel, K. J., & Patel, M. M.. "Nanostructured lipid carriers: A novel approach for drug delivery." Journal of Drug Delivery Science and Technology, (2013) 23(5), 574-581.DOI: 10.1016/S1773-2247(13)50039-7
30. Duarte, J. L., & Valenzuela, C.. "Nanostructured lipid carriers: Design, characterization and applications." Biomaterials Science, (2017). 5(6), 917-927.DOI: 10.1039/C7BM00142A
31. Kumar, A., & Yadav, S. K.. "Nanostructured lipid carriers (NLC): A novel drug delivery system."International Journal of Pharmaceutical Sciences and Research, (2016). 7(5), 1973-1981.DOI: 10.13040/IJPSR.0975-8232.7(5).1973-81
32. Daniyal, M., & Khan, M.. "Nanostructured lipid carriers: An overview." International Journal of Drug Delivery Technology, (2018).8(1), 32-39.DOI: 10.25258/ijddt.v8i1.18112
33. Pignatello, R., & Puglisi, G.. "Nanostructured lipid carriers for drug delivery." Current Drug Delivery, (2010). 7(3), 313-320. DOI: 10.2174/156720110791278371
34. Yuan, H., & Chen, X.. "Nanostructured lipid carriers: An overview." Journal of Nanomedicine & Nanotechnology, (2015). 6(3), 1-8.DOI: 10.4172/2157-7439.1000322
35. Stability Issues - Wissing, S. A., & Müller, R. H.. "Solid lipid nanoparticles and nanostructured lipid carriers: Production, characterization, and applications." Advanced DrugDelivery Reviews, 54(Supplement), (2002). S13-S21.DOI: 10.1016/S0169-409X(02)00173-4
36. Scale-Up Production - Müller, R. H., & Lucks, J.. "Nanostructured lipid carriers (NLC) in drug delivery." Journal of Drug Delivery Science and Technology, (2015).30, 98-105. DOI: 10.1016/j.jddst.2015.07.004
37. Regulatory Hurdles- Cohen, J.. "The safety of nanomedicines: Regulatory hurdles." Nature Reviews Drug Discovery, (2008). 7(4), 299-300.DOI: 10.1038/nrd2006
38. Cost of Production- Patel, K. J., & Patel, M. M.. "Nanostructured lipid carriers: A novel approach for drug delivery." Journal of Drug Delivery Science and Technology, (2013).23(5), 574-581.DOI: 10.1016/S1773-2247(13)50039-7
39. Drug Compatibility - Duarte, J. L., & Valenzuela, C.. "Nanostructured lipid carriers: Design, characterization and applications." Biomaterials Science, (2017). 5(6), 917-927.DOI: 10.1039/C7BM00142A

How to cite this article:
Swaraj S. Warkad et al. Ijppr.Human, 2025; Vol. 31 (4): 100-117.

Conflict of Interest Statement: All authors have nothing else to disclose.

Mr Swaraj Subhash Warkad[1*]

M. Pharm student, Department of Pharmaceutics, Krishnarao Bhegade Indrayani Institute of Pharmaceutical Education and Research, Talegaon Dabhade,

Talegaon – Chakan Road, Talegaon Dabhade, Taluka Maval, District Pune -410507. Maharashtra, India.

	**Mr Shyam S. Awate** Associate Professor, Department of Pharmaceutics, Krishnarao Bhegade Indrayani Institute of Pharmaceutical Education and Research, Talegaon Dabhade, Talegaon – Chakan Road, Talegaon Dabhade, Taluka Maval, District Pune -410507. Maharashtra, India.
	**Mr Yuraj Panjabrao Kadam** M. Pharm student, Department of Pharmaceutics, Sudharkarao Naik Institute of Pharmacy,Pusad. Sudhakarrao Naik Institute of Pharmacy, Nagpur Road, Pusad- 445204, Dist.- Yavatmal, Maharashtra, India.
	Mr Sanjay R. Arote Principal, Krishnarao Bhegade Indrayani Institute of Pharmaceutical Education and Research, Talegaon Dabhade. Talegaon – Chakan Road, Talegaon Dabhade, Taluka Maval, District Pune -410507. Maharashtra, India.
	**Mr Ramprasad D. Kadam** M. Pharm student, Department of Pharmaceutics, Krishnarao Bhegade Indrayani Institute of Pharmaceutical Education and Research, Talegaon Dabhade. Talegaon – Chakan Road, Talegaon Dabhade, Taluka Maval, District Pune -410507. Maharashtra, India.
	**Mr Mangesh Mahesh Galbale** M. Pharm student, Department of Pharmaceutics, Krishnarao Bhegade Indrayani Institute of Pharmaceutical Education and Research, Talegaon Dabhade. Talegaon – Chakan Road, Talegaon Dabhade, Taluka Maval, District Pune -410507. Maharashtra, India.

Mr Mahadevan Raju Swamy

Assistant Professor,Department of Medicinal Chemistry, Krishnarao Bhegade Indrayani Institute of Pharmaceutical Education and Research, Talegaon Dabhade, Maval, Pune - 410507. India.

Talegaon – Chakan Road, Talegaon Dabhade, Taluka Maval, District Pune -410507. Maharashtra, India.